Ovid Therapeutics Inc.
OVID
Rank in Stocks
#11508
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating... Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy. Beyond these, Ovid is also advancing OV882, a short hairpin RNA (shRNA) gene therapy designed to treat Angelman syndrome, and OV815, targeting neurological disorders connected to the kinesin-family of proteins. To bolster its research and development efforts, Ovid maintains licensing and collaborative agreements with prominent entities such as Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Marinus Pharmaceuticals, Inc. Established in 2014, the company's corporate headquarters are situated in New York, New York.
Share Price
$2.85
Last synced: 2026-11-09
Market Cap
$556.60M
Change (1 day)
0.00%
Change (1 year)
115.91%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Ovid Therapeutics Inc. (OVID)
Category
Healthcare
Operating Margin for Ovid Therapeutics Inc. (OVID)
Operating Margin as of November 2026 TTM: -3,686.67%
According to Ovid Therapeutics Inc.'s latest financial reports, its current operating margin (TTM) is -3,686.67%. At the end of 2025 the company had an operating margin of -585.20%.
Operating Margin history for Ovid Therapeutics Inc. from 2014 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -3,686.67% | 529.98% |
| 2025 | -585.20% | -94.65% |
| 2024 | -10,933.75% | -27.70% |
| 2023 | -15,122.70% | 309.12% |
| 2022 | -3,696.44% | -6,301.04% |
| 2021 | 59.61% | -109.24% |
| 2020 | -645.40% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.01% |
US
|
|
| -149.01% | -99.96% |
US
|
|
| 25.57% | -100.01% |
AU
|
|
| 31.23% | -100.01% |
BE
|
|
| 29.35% | -100.01% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Ovid Therapeutics Inc.'s operating margin
What is Ovid Therapeutics Inc.'s operating margin?
Ovid Therapeutics Inc.'s operating margin is -3,686.67%, as of Nov 2026.
What was Ovid Therapeutics Inc.'s operating margin in 2025?
In 2025, Ovid Therapeutics Inc.'s operating margin was -585.20%, compared with -10,933.75% in 2024.
How has Ovid Therapeutics Inc.'s operating margin changed since 2020?
From 2020 to 2025, Ovid Therapeutics Inc.'s operating margin was highest in 2021 (59.61%) and lowest in 2023 (-15,122.70%).
How does Ovid Therapeutics Inc.'s operating margin compare with similar companies?
Ovid Therapeutics Inc.'s operating margin (-3,686.67%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.